281 related articles for article (PubMed ID: 30423148)
1. Molecular-targeted therapies and precision medicine for endometrial cancer.
Mitamura T; Dong P; Ihira K; Kudo M; Watari H
Jpn J Clin Oncol; 2019 Feb; 49(2):108-120. PubMed ID: 30423148
[TBL] [Abstract][Full Text] [Related]
2. New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Rodriguez-Freixinos V; Karakasis K; Oza AM
Curr Oncol Rep; 2016 Apr; 18(4):23. PubMed ID: 26922329
[TBL] [Abstract][Full Text] [Related]
3. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
4. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.
Lheureux S; Oza AM
Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. Molecular therapy as a future strategy in endometrial cancer.
Thanapprapasr D; Thanapprapasr K
Asian Pac J Cancer Prev; 2013; 14(6):3419-23. PubMed ID: 23886121
[TBL] [Abstract][Full Text] [Related]
7. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options.
MacKay HJ; Freixinos VR; Fleming GF
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32239967
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
10. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
11. Personalized therapy in endometrial cancer: challenges and opportunities.
Westin SN; Broaddus RR
Cancer Biol Ther; 2012 Jan; 13(1):1-13. PubMed ID: 22198566
[TBL] [Abstract][Full Text] [Related]
12. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
13. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
14. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.
Lee PS; Secord AA
Cancer Treat Rev; 2014 May; 40(4):507-12. PubMed ID: 24332498
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic biomarkers in endometrial cancer.
Dong P; Kaneuchi M; Konno Y; Watari H; Sudo S; Sakuragi N
Biomed Res Int; 2013; 2013():130362. PubMed ID: 23819113
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
20. Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience.
Salutari V; Ghizzoni V; Carbone MV; Giudice E; Cappuccio S; Fanfani F; Scambia G; Lorusso D
Int J Gynecol Cancer; 2023 Apr; 33(4):514-520. PubMed ID: 36746489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
